News-Detail

Helmholtz Biomedical Engineering Initiative

The Helmholtz Association is launching a nationwide biomedical engineering initiative to accelerate technology development and transfer activities. Led by its established Health Centers, “Helmholtz Biomedical Engineering” brings together cutting-edge…

Helmholtz Munich coordinates a new €4.9 million Horizon Europe project that will support cities with science-based strategies to reduce pollution and protect public health.

corona virus 2019-ncov flu outbreak, covid-19 3d banner illustration, microscopic view of floating influenza virus cells

The German National Cohort (NAKO) contributes its scientific expertise to the National Decade of Post-Infectious Diseases initiated by the Federal Ministry of Research, Technology and Space (BMFTR). With two central projects, it makes an important…

Ancient viral remnants embedded in the human genome may be an overlooked driver of Alzheimer’s disease. Dr. Michelle Vincendeau at Helmholtz Munich is investigating how so-called endogenous retroviruses influence disease-relevant mechanisms in human…

Numerous genetic studies have identified many risk variants for type 2 diabetes (T2D) – but which genes and proteins are actually involved in the disease mechanisms? An international team led by Helmholtz Munich has now used globally collected…

Cardiovascular diseases are the leading cause of death worldwide, and lowering blood lipids is a central strategy to reduce risk. Bempedoic acid, a recently approved cholesterol-lowering drug, has now been shown by researchers at Helmholtz Munich to…

Helmholtz Biomedical Engineering Initiative: Shaping the Future of Health

PUREPOLIS: New EU Project for Cleaner, Healthier Cities

NAKO Participates in the National Decade of Post-Infectious Diseases

Can Ancient Viral Remnants Trigger Alzheimer’s Disease?

Big Data Make Hidden Genetic Drivers of Type 2 Diabetes Visible

Cholesterol-Lowering Drug Found to Target Key Metabolic Switch